Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Immunovia AB ( (SE:IMMNOV) ) just unveiled an update.
Immunovia has appointed Natalie Carfora as Vice President of Market Access and Reimbursement to enhance coverage and U.S. reimbursement for its PancreaSure test. Carfora’s return to Immunovia is strategic, given her extensive experience and previous success in securing coverage policies and managing revenue cycles in the medical diagnostics field. Her leadership is expected to drive business-critical growth and support the company’s mission of early pancreatic cancer detection.
More about Immunovia AB
Immunovia AB is a diagnostic company focused on increasing survival rates for pancreatic cancer patients through early detection. The company develops and commercializes tests to detect proteins and blood-based antibodies indicating pancreatic cancer, collaborating with healthcare providers and experts to make these tests available to high-risk individuals. The USA is a significant market for pancreatic cancer detection, with an estimated 1.8 million high-risk individuals who could benefit from annual surveillance testing.
YTD Price Performance: -20.70%
Average Trading Volume: 3,601,548
Current Market Cap: SEK132.7M
See more insights into IMMNOV stock on TipRanks’ Stock Analysis page.